Select Page

International

Lung Cancer Summit

Save The Date!

October 7: Lausanne University Hospital (CHUV)

Join us virtually online or on site in Lausanne!

 

REGISTRATION TO OPEN ON JULY 1st

 

 

 

Watch Last Year's Meeting

Alfredo Addeo, MD
Alfredo Addeo, MD

Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

Solange Peters, MD-PhD
Solange Peters, MD-PhD

Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at Lausanne University Hospital, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from Lausanne University Hospital, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Follow Us For The Latest News on Twitter & LinkedIn

What do we know about current #EGFR and #ALK inhibitors for #NSCLC? 🤔🫁

Check out this detailed review by @alissajcooper @LeciaSequist, and @JessicaJLinMD who outline third gen EGFR and ALK inhibitors and ways in which to tackle resistance ➡️ https://go.nature.com/3PjRLMY

👇👇

Image for the Tweet beginning: What do we know about

Study provides evidence for the prognostic value of ctDNA-based #MRD detection in people with #NSCLC after surgery 🫁 ➡️ https://bit.ly/3PmH905

We can't wait to talk more about #LiquidBiopsy, neoadjuvant, and adjuvant therapies for #LungCancer at this year's #LungSummit!

Image for the Tweet beginning: Study provides evidence for the

Study suggests entrectinib prolongs survival in ROS1 #TKI naïve patients with ROS1 fusion-positive #NSCLC, with modest activity in patients with #CNS-only progression post-crizotinib 💊🫁

See the study by @alexdrilon, Salvatore Siena & colleagues ➡️ https://bit.ly/3shGvab

Image for the Tweet beginning: Study suggests entrectinib prolongs survival

Screening is important to identify high-risk individuals with #LungCancer so that they may have the best chances of curative treatment 🫁

See this new study highlighting key factors needed to allow for successful screening programs across Europe!

➡️ https://bit.ly/3MJtCO5

👇

Image for the Tweet beginning: Screening is important to identify

Results from the JCOG0802 trial shed light on the clinical benefit of segmentectomy over lobectomy in terms of overall survival for early-stage #LungCancer 🫁

Check out the study in @TheLancet by Hisashi Saji, Hisao Asamura and colleagues ➡️ https://bit.ly/3rUAfF3

#LCSM

Image for the Tweet beginning: Results from the JCOG0802 trial

New study provides a resource of 46 PDX/CDX models derived from 33 donors with #SCLC, offering insight into the genomic & protein landscape of SCLC subtypes 🫁

#OpenAccess article in @NatureComms by @CaeserRebeccs, @triparnasen & colleagues ➡️ https://go.nature.com/3xLQf00

#LCSM

Image for the Tweet beginning: New study provides a resource

Results from the phase 3 #CheckMate816 trials suggest nivolumab plus chemotherapy increased event-free survival in people with #NSCLC 🫁

See the study in @NEJM by @FordePatrick, @DoctorJSpicer, @nicogirardcurie and colleagues ➡️ https://bit.ly/3M8C5d6

#LCSM #LungCancer

Image for the Tweet beginning: Results from the phase 3
Load More...